Ginkgo rises on $31 mln contract to develop vaccine adjuvants

Ginkgo Bioworks Holdings

15/02/2024 14:18

** Shares of biotech company Ginkgo Bioworks  DNA.N  rise
2.7% to $1.53 premarket
    ** U.S. Defense Threat Reduction Agency has awarded a 5-year
contract worth $31 mln to Gingko and Massachusetts-based
SaponiQx to discover and develop vaccine adjuvants - DNA
    ** The partners aim to demonstrate the ability of these
novel adjuvants to protect against challenges from biothreat
agents such as the plague
    ** An adjuvant is an ingredient used in some vaccines that
helps create a stronger immune response in people receiving the
dose
    ** Up to last close, stock down 13.8% in the last 12 months
    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))